• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 28, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Janus bases among The Scientist’s Top Innovations of 2019

Bioengineer by Bioengineer
December 5, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Invented at Carnegie Mellon, the bivalent nucleic acid recognition platform is being used to develop treatments for rare genetic diseases

IMAGE

Credit: Carnegie Mellon University


The Scientist Magazine has named Janus bases as one of its Top 10 Innovations of 2019. Carnegie Mellon University Chemistry Professor Danith Ly invented the molecules, and they are being used to create new treatments for genetic diseases and disorders.

Janus bases are used to make two-sided synthetic analogs to DNA and RNA. The molecules can recognize and bind to DNA and RNA under normal physiological conditions, making them a promising platform for treating a wide range of genetic conditions including neurological diseases and muscular dystrophies.

Janus bases are being developed by NeuBase Therapeutics as a novel molecular platform for RNA-targeting drugs that silence or alter the expression of genes for the treatment of rare genetic diseases. NeuBase was founded and is led by CEO Dietrich Stephan, an alumnus of Carnegie Mellon’s Department of Biological Sciences. Ly serves as the company’s chief scientific officer.

Ly, who directs Carnegie Mellon’s Biomolecular Design and Discovery Institute, is a leading expert in creating peptide nucleic acids (PNAs). PNAs contain the same base pairs as DNA and RNA, but have a synthetic backbone. To further this technology, Ly created Janus bases, a set of bivalent nucleic acid recognition elements that can bind to any possible combination found in the genetic code. As a result, PNAs made with Janus bases can enter the double helix of DNA and RNA, search for detrimental sequences and bind to each side of the two strands and prevent a gene from malfunctioning.

Neubase uses PNAs with Janus bases to target and bind to mutant RNA and silence harmful genes by preventing translation or altering splicing of the genetic material. As a result, harmful proteins that cause disease are no longer produced.

###

Ly’s early work on Janus bases was made possible through a gift from the DSF Charitable Foundation to Carnegie Mellon’s Center for Nucleic Acids Science & Technology.

In its annual list of Top 10 Innovations, The Scientist identifies the latest and greatest tools, technologies and techniques in the life sciences. The innovations included on the list are selected by expert panels of independent judges. The Scientist is a publication for life-science professionals that is dedicated to covering a wide range of biological fields.

Media Contact
Jocelyn Duffy
[email protected]
412-268-9982

Original Source

https://www.cmu.edu/mcs/news-events/2019/1202_janus-bases-top-innovation.html

Tags: BiochemistryBiologyBiotechnologyChemistry/Physics/Materials SciencesGene TherapyGenesGeneticsMedicine/HealthneurobiologyPharmaceutical Sciences
Share13Tweet8Share2ShareShareShare2

Related Posts

Advancing Exosome Therapy for Premature Ovarian Insufficiency

October 28, 2025

Gestational Diabetes Impacts Offspring’s Neurodevelopment: Study Reveals

October 28, 2025

Kidney Transplants from Circulatory Death Donors: Outcomes Reviewed

October 28, 2025

Impact of Age and Eye Metrics on Myopia

October 28, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1288 shares
    Share 514 Tweet 322
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    198 shares
    Share 79 Tweet 50
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    135 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Biofertilizers: Future of Sustainable Agriculture Unveiled

Advancing Exosome Therapy for Premature Ovarian Insufficiency

Uncovering Hybridization in Lycium Species via Genomics

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.